PL2897644T3 - Skojarzenie farmaceutyczne zawierające inhibitor kinazy 3-fosfatydyloinozytolu i inhibitor aromatazy - Google Patents

Skojarzenie farmaceutyczne zawierające inhibitor kinazy 3-fosfatydyloinozytolu i inhibitor aromatazy

Info

Publication number
PL2897644T3
PL2897644T3 PL13770771T PL13770771T PL2897644T3 PL 2897644 T3 PL2897644 T3 PL 2897644T3 PL 13770771 T PL13770771 T PL 13770771T PL 13770771 T PL13770771 T PL 13770771T PL 2897644 T3 PL2897644 T3 PL 2897644T3
Authority
PL
Poland
Prior art keywords
inhibitor
phosphatidylinositol
pharmaceutical combination
aromatase
kinase inhibitor
Prior art date
Application number
PL13770771T
Other languages
English (en)
Inventor
Michael GOLDBRUNNER
Xizhong Huang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2897644T3 publication Critical patent/PL2897644T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13770771T 2012-09-20 2013-09-18 Skojarzenie farmaceutyczne zawierające inhibitor kinazy 3-fosfatydyloinozytolu i inhibitor aromatazy PL2897644T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261703533P 2012-09-20 2012-09-20
US201261708070P 2012-10-01 2012-10-01
PCT/US2013/060292 WO2014047109A1 (en) 2012-09-20 2013-09-18 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor
EP13770771.7A EP2897644B1 (en) 2012-09-20 2013-09-18 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and an aromatase inhibitor

Publications (1)

Publication Number Publication Date
PL2897644T3 true PL2897644T3 (pl) 2018-11-30

Family

ID=49263471

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13770771T PL2897644T3 (pl) 2012-09-20 2013-09-18 Skojarzenie farmaceutyczne zawierające inhibitor kinazy 3-fosfatydyloinozytolu i inhibitor aromatazy

Country Status (21)

Country Link
US (1) US9532982B2 (pl)
EP (1) EP2897644B1 (pl)
JP (1) JP6212563B2 (pl)
KR (1) KR102220965B1 (pl)
CN (1) CN104661681B (pl)
AU (1) AU2013318205B2 (pl)
BR (1) BR112015004152A2 (pl)
CA (1) CA2880506C (pl)
CY (1) CY1120984T1 (pl)
DK (1) DK2897644T3 (pl)
ES (1) ES2686689T3 (pl)
HR (1) HRP20181413T1 (pl)
HU (1) HUE040520T2 (pl)
IN (1) IN2015DN00735A (pl)
LT (1) LT2897644T (pl)
MX (1) MX356278B (pl)
PL (1) PL2897644T3 (pl)
PT (1) PT2897644T (pl)
RU (1) RU2651023C2 (pl)
SI (1) SI2897644T1 (pl)
WO (1) WO2014047109A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939319A (zh) * 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
PA8809001A1 (es) * 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
US20110178070A1 (en) * 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
CY1120984T1 (el) 2019-12-11
SI2897644T1 (sl) 2018-10-30
AU2013318205A1 (en) 2015-02-26
IN2015DN00735A (pl) 2015-07-10
RU2651023C2 (ru) 2018-04-18
HRP20181413T1 (hr) 2018-10-19
HUE040520T2 (hu) 2019-03-28
EP2897644B1 (en) 2018-06-06
ES2686689T3 (es) 2018-10-19
PT2897644T (pt) 2018-10-16
MX356278B (es) 2018-05-22
JP6212563B2 (ja) 2017-10-11
KR102220965B1 (ko) 2021-02-26
US20150231124A1 (en) 2015-08-20
AU2013318205B2 (en) 2016-05-19
RU2015111171A (ru) 2016-11-10
JP2015532927A (ja) 2015-11-16
CA2880506C (en) 2021-04-20
EP2897644A1 (en) 2015-07-29
CN104661681B (zh) 2018-07-03
MX2015003657A (es) 2015-06-05
CN104661681A (zh) 2015-05-27
DK2897644T3 (en) 2018-09-10
KR20150056778A (ko) 2015-05-27
WO2014047109A1 (en) 2014-03-27
BR112015004152A2 (pt) 2017-07-04
LT2897644T (lt) 2018-09-25
CA2880506A1 (en) 2014-03-27
US9532982B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
HK1220968A1 (zh) 磷脂酰肌醇 -激酶抑制劑
HK1208911A1 (en) Identification of patients in need of pd-l1 inhibitor cotherapy pd-l1
HK1211206A1 (en) Virus-containing formulation and use thereof
HK1204773A1 (en) Pyrazole derivative and use thereof for medical purposes
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
IL237321A0 (en) ddr2 inhibitors and pharmaceutical preparations containing them
GB201219678D0 (en) Ketone body inhibitors and uses thereof
IL237456A0 (en) Pharmaceutical preparation of phosphatidylinositol 3-kinase inhibitor
HRP20181413T1 (hr) Farmaceutska kombinacija koja sadrži inhibitor fosfatidilinositol 3-kinaze i inhibitor aromataze
IL239872A0 (en) Metriptase inhibitors and pharmaceutical preparations containing them